Simlandi contains adalimumab-ryvk, a biosimilar to Humira® (adalimumab), and is a tumor necrosis factor (TNF) blocker used to treat a range of autoimmune and inflammatory diseases. As a biologic therapy, Simlandi helps reduce inflammation by targeting and inhibiting TNF-α, a key cytokine involved in the body's inflammatory response.

Simlandi is approved for multiple indications, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. By controlling excessive immune activity, it can help reduce symptoms, improve physical function, and slow disease progression in eligible patients.

The medication is administered by subcutaneous injection and is available as a high-concentration, citrate-free formulation (40 mg/0.4 mL). Treatment schedules vary depending on the condition being treated, patient age, and clinical response. Patients may self-administer the injection after receiving appropriate training from a healthcare professional.

As a biosimilar, Simlandi has been demonstrated to have no clinically meaningful differences from Humira in terms of safety, purity, and effectiveness. It provides an additional treatment option that may improve access to biologic therapy for patients with chronic inflammatory diseases.

Common side effects may include injection-site reactions, upper respiratory tract infections, headache, rash, and nausea. Serious risks include serious infections, tuberculosis, opportunistic infections, certain malignancies, and allergic reactions. Patients should undergo appropriate screening and monitoring before and during treatment.